Study of Efficacy, Safety and Complications of COVID 19 Vaccine on Adults and Elderly with and without Chronic Diseases

Authors

Nasser Alhamshary, Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.
Abdullah Hendawy El Shahat, Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.
Mohamed Gharib Mohamed, Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.
Abdel Kareem Mohammad Abdel Rahim, Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.Follow

Corresponding Author

Abdel Kareem Mohammad Abdel Rahim

Document Type

Original Article

Abstract

Background: Anti-CoV-2 vaccines were developed in a much shorter time than previous vaccines. The aim of this work was to assess the efficacy of COVID-19 vaccine on adult and elderly with and without chronic diseases and evaluate safety, side effects and complications of COVID19 vaccine on adult and elderly with and without chronic diseases.

Methods: Prospective observational cohort study was carried out on 100 subjects received COVID-19 vaccine. Subjects were divided into three groups: Group (1): thirty healthy young persons aging 18-45 years old, who received COVID-19 vaccine (5 subjects received Pfizer vaccine, 9 received AstraZeneca, and 16 received Sinopharm. Group (2): thirty-five persons, aging > 50 years without chronic diseases received COVID-19 vaccine (6 subjects received Pfizer vaccine, 11 received AstraZeneca, and 18 received Sinopharm. Group (3): thirty-five persons, aging > 50 years with chronic diseases (DM-HTN-IHD-BA-COPD-Hypothyroidism) received COVID19 vaccine (6 subjects received Pfizer vaccine, 10 received AstraZeneca, and 19 received Sinopharm).

Results: As regard 1st and 2nd dose side effects, highly significant (p-value < 0.05) increased percentage of myalgia, diarrhea, nausea, pain at injection site and dyspnea in AstraZeneca group when compared with Pfizer group and Sinopharm group.

Conclusions: Adverse effects of all vaccines are moderate in frequency, mild in severity, and short-lived. Statistical significant increased percentage of side effects in AstraZeneca group when compared with Pfizer group and Sinopharm group. Serum levels of SARS-CoV-2 spike IgG antibody at 21 days after the second vaccine dose were similar in all groups without significant difference between different vaccines.

Keywords

COVID 19 Vaccine, Adults, Elderly, Chronic Diseases, Side Effects

Subject Area

Chest, Clinical Multidisciplinary, General Medicine, Internal Medicine, Public health

How to Cite This Article

Alhamshary, Nasser; Shahat, Abdullah Hendawy El; Mohamed, Mohamed Gharib; and Rahim, Abdel Kareem Mohammad Abdel (2023) "Study of Efficacy, Safety and Complications of COVID 19 Vaccine on Adults and Elderly with and without Chronic Diseases," Al-Azhar International Medical Journal: Vol. 4: Iss. 9, Article 16.
DOI: https://doi.org/10.58675/2682-339X.2019